Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
2.970
-0.070 (-2.30%)
At close: Sep 16, 2025, 4:00 PM EDT
2.969
-0.001 (-0.03%)
After-hours: Sep 16, 2025, 5:34 PM EDT
Atea Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
56
Market Cap
235.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 351.37M | 302.73M | 622.49% |
| Dec 31, 2020 | 48.63M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AVIR News
- 7 days ago - Atea Pharmaceuticals, Inc. (AVIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Atea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America - GlobeNewsWire
- 4 months ago - Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 - GlobeNewsWire